OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press21410.17650/1818-8346-2016-11-4-32-48HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯIKZF1 DELETIONS ARE INDEPENDENT PROGNOSTIC FACTOR IN PEDIATRIC B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIAДЕЛЕЦИИ ГЕНА IKZF1 – НЕЗАВИСИМЫЙ ПРОГНОСТИЧЕСКИЙ ФАКТОР У ДЕТЕЙ С ОСТРЫМ ЛИМФОБЛАСТНЫМ ЛЕЙКОЗОМ ИЗ B-ЛИНЕЙНЫХ ПРЕДШЕСТВЕННИКОВTsaurG. A.ЦаурГ. А.
Russian Federation

32 Serafimy Deryabinoy St., Ekaterinburg 620149, Russia; 22a Karla Marksa St., Ekaterinburg 620026, Russia; 19 Mira St., Ekaterinburg 620002, Russia; 3 Repina St., Ekaterinburg 620030, Russ

Григорий Анатольевич Цаур.

620149 Екатеринбург, ул. Серафимы Дерябиной, 32;  620026 Екатеринбург, ул. Карла Маркса, 22а; Р620002 Екатеринбург, ул. Мира, 19; 620030 Екатеринбург, ул. Репина, 3; tsaur@mail.ru

tsaur@mail.ruDruyA. Е.ДруйА. Е.
Russian Federation

22a Karla Marksa St., Ekaterinburg 620026, Russia; 1 Samory Mashela St., Moscow 117997, Russia

620026 Екатеринбург, ул. Карла Маркса, 22а; 117997 Москва, ул. Саморы Машела, 1

SolodonikovA. G.СолодовниковА. Г.
Russian Federation

22a Karla Marksa St., Ekaterinburg 620026, Russia; 3 Repina St., Ekaterinburg 620030, Russi

620026 Екатеринбург, ул. Карла Маркса, 22а

PopovA. M.ПоповА. М.
Russian Federation

1 Samory Mashela St., Moscow 117997, Russia

117997 Москва, ул. Саморы Машела, 1

ShapochnikA. P.ШапочникА. П.
Russian Federation

11 Gagarina Prospekt, Orenburg 460021, Russia

460021 Оренбург, проспект Гагарина, 11

VakhoninaL. V.ВахонинаЛ. В.
Russian Federation

32 Serafimy Deryabinoy St., Ekaterinburg 620149, Russia; 22a Karla Marksa St., Ekaterinburg 620026, Russia

620149 Екатеринбург, ул. Серафимы Дерябиной, 32;   620026 Екатеринбург, ул. Карла Маркса, 22а

VlasovaА. А.ВласоваА. А.
Russian Federation

32 Serafimy Deryabinoy St., Ekaterinburg 620149, Russia

620149 Екатеринбург, ул. Серафимы Дерябиной, 32;

RigerТ. О.РигерТ. О.
Russian Federation

32 Serafimy Deryabinoy St., Ekaterinburg 620149, Russia; 22a Karla Marksa St., Ekaterinburg 620026, Russia

620149 Екатеринбург, ул. Серафимы Дерябиной, 32;  620026 Екатеринбург, ул. Карла Маркса, 22а

VerzhbitskayaT. Yu.ВержбицкаяТ. Ю.
Russian Federation

32 Serafimy Deryabinoy St., Ekaterinburg 620149, Russia; 22a Karla Marksa St., Ekaterinburg 620026, Russia

620149 Екатеринбург, ул. Серафимы Дерябиной, 32;  620026 Екатеринбург, ул. Карла Маркса, 22а

OlshanskayaYu. V.ОльшанскаяЮ. В.
Russian Federation

1 Samory Mashela St., Moscow 117997, Russia

117997 Москва, ул. Саморы Машела, 1

ShorikovE. V.ШориковЕ. В.
Russian Federation

1/9 4th Dobryninskiy Pereulok, Moscow 119049, Russia

119049 Москва, 4-й Добрынинский переулок, 1/9

ArakaevО. R.АракаевО. Р.
Russian Federation

32 Serafimy Deryabinoy St., Ekaterinburg 620149, Russia; 22a Karla Marksa St., Ekaterinburg 620026, Russia

 620149 Екатеринбург, ул. Серафимы Дерябиной, 32; 620026 Екатеринбург, ул. Карла Маркса, 22а

SavelievL. I.СавельевЛ. И.
Russian Federation

32 Serafimy Deryabinoy St., Ekaterinburg 620149, Russia; 22a Karla Marksa St., Ekaterinburg 620026, Russia; 3 Repina St., Ekaterinburg 620030, Russia

620149 Екатеринбург, ул. Серафимы Дерябиной, 32;  620026 Екатеринбург, ул. Карла Маркса, 22а; 620030 Екатеринбург, ул. Репина, 3

FechinaL. G.ФечинаЛ. Г.
Russian Federation

32 Serafimy Deryabinoy St., Ekaterinburg 620149, Russia

620149 Екатеринбург, ул. Серафимы Дерябиной, 32

Regional Children’s Clinical Hospital No 1Областная детская клиническая больница № 1Research Institute of Medical Cell TechnologiesИнститут медицинских клеточных технологийUral Federal University named after the First President of Russia B.N. YeltsinУральский федеральный университет имени первого Президента России Б.Н. ЕльцинаUral State Medical University, Ministry of Health of RussiaУральский государственный медицинский университетFederal Research Сentre of Pediatric Hematology, Oncology, and Immunology named after Dmitriy RogachevФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии имени Дмитрия РогачеваUral State Medical UniversityФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии имени Дмитрия РогачеваFederal Research Сentre of Pediatric Hematology, Oncology, and Immunology named after Dmitriy RogachevОренбургский областной клинический онкологический диспансерOrenburg Regional Clinical Oncological DispensaryОбластная детская клиническая больница № 1Regional Children’s Clinical Hospital No 1Институт медицинских клеточных технологийResearch Institute of Medical Cell TechnologiesОбластная детская клиническая больница № 1Research Institute of Medical Cell TechnologiesФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии имени Дмитрия РогачеваFederal Research Сentre of Pediatric Hematology, Oncology, and Immunology named after Dmitriy RogachevМорозовская детская городская клиническая больница Департамента здравоохранения г. МосквыMorozov Pediatric City Clinical Hospital, Moscow Healthcare DepartmentОбластная детская клиническая больница № 1Research Institute of Medical Cell TechnologiesУральский государственный медицинский университетUral State Medical University, Ministry of Health of RussiaОбластная детская клиническая больница № 1Regional Children’s Clinical Hospital No 103122016114324803012017030120172016https://oncohematology.abvpress.ru/ongm/article/view/214

acute lymphoblastic leukemiachildrenprognosisrisk factorsIKZF1 deletionsострый лимфобластный лейкоздетипрогнозфакторы рискаделеции гена IKZF11. Olsson L., Johansson B. Ikaros and leukaemia. Br J Haematol 2015;169(4): 479–91. DOI: 10.1111/bjh.13342. PMID: 25753742.Olsson L., Johansson B. Ikaros and leukaemia. Br J Haematol 2015;169(4): 479–91. DOI: 10.1111/bjh.13342. PMID: 25753742.2. Payne K.J., Huang G., Sahakian E. et al. Ikaros isoform x is selectively expressed in myeloid differentiation. J Immunol 2003;170(6):3091–8. PMID: 12626565.Payne K.J., Huang G., Sahakian E. et al. Ikaros isoform x is selectively expressed in myeloid differentiation. J Immunol 2003;170(6):3091–8. PMID: 12626565.3. Francis O.L., Payne J.L., Su R.J., Payne K.J. Regulator of myeloid differentiation and function: the secret life of Ikaros. World J Biol Chem 2011;2(6):119–25. DOI: 10.4331/wjbc.v2.i6.119. PMID: 21765977.Francis O.L., Payne J.L., Su R.J., Payne K.J. Regulator of myeloid differentiation and function: the secret life of Ikaros. World J Biol Chem 2011;2(6):119–25. DOI: 10.4331/wjbc.v2.i6.119. PMID: 21765977.4. Morgan B., Sun L., Avitahl N. et al. Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J 1997;16(8):2004–13. DOI: 10.1093/emboj/16.8.2004. PMID: 9155026.Morgan B., Sun L., Avitahl N. et al. Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J 1997;16(8):2004–13. DOI: 10.1093/emboj/16.8.2004. PMID: 9155026.5. Kelley C., Ikeda T., Koipally J. et al. Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. Curr Biol 1998;8(9):508–15. PMID: 9560339.Kelley C., Ikeda T., Koipally J. et al. Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. Curr Biol 1998;8(9):508–15. PMID: 9560339.6. Iacobucci I., Iraci N., Messina M. et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One 2012;7(7):e40934. DOI: 10.1371/journal.pone.0040934. PMID: 22848414.Iacobucci I., Iraci N., Messina M. et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One 2012;7(7):e40934. DOI: 10.1371/journal.pone.0040934. PMID: 22848414.7. Gene: IKZF1. URL: http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000185811;r=7:50304124-50405101 (last access date 02.12.2016).Gene: IKZF1. URL: http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000185811;r=7:50304124-50405101 (last access date 02.12.2016).8. Koipally J., Georgopoulos K. Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity. J Biol Chem 2000;275(26):19594–602. DOI: 10.1074/jbc.M000254200. PMID: 10766745.Koipally J., Georgopoulos K. Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity. J Biol Chem 2000;275(26):19594–602. DOI: 10.1074/jbc.M000254200. PMID: 10766745.9. Joshi I., Yoshida T., Jena N. et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 2014;15(3):294–304. DOI: 10.1038/ni.2821. PMID: 24509510.Joshi I., Yoshida T., Jena N. et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 2014;15(3):294–304. DOI: 10.1038/ni.2821. PMID: 24509510.10. Mullighan C., Su X., Zhang J. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. New Engl J Med 2009;360(5):470–80. DOI: 10.1056/NEJMoa0808253. PMID: 19129520.Mullighan C., Su X., Zhang J. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. New Engl J Med 2009;360(5):470–80. DOI: 10.1056/NEJMoa0808253. PMID: 19129520.11. Kuiper R., Waanders E., van der Velden V. et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010;24(7):1258–64. DOI: 10.1038/leu.2010.87. PMID: 20445578.Kuiper R., Waanders E., van der Velden V. et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010;24(7):1258–64. DOI: 10.1038/leu.2010.87. PMID: 20445578.12. Waanders E., van der Velden V., van der Schoot C. et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79 % of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011;25(2):254–8. DOI: 10.1038/leu.2010.275. PMID: 21102428.Waanders E., van der Velden V., van der Schoot C. et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79 % of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011;25(2):254–8. DOI: 10.1038/leu.2010.275. PMID: 21102428.13. Roberts K., Li Y., Payne-Turner D. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371(11):1005–15. DOI: 10.1056/NEJMoa1403088. PMID: 25207766.Roberts K., Li Y., Payne-Turner D. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371(11):1005–15. DOI: 10.1056/NEJMoa1403088. PMID: 25207766.14. Olsson L., Albitar F., Castor A. et al. Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations of IKZF1. Genes Chromosomes Cancer 2015;54(5):315–25. DOI: 10.1002/gcc.22245. PMID: 25727050.Olsson L., Albitar F., Castor A. et al. Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations of IKZF1. Genes Chromosomes Cancer 2015;54(5):315–25. DOI: 10.1002/gcc.22245. PMID: 25727050.15. Mullighan C.G., Miller C.B., Radtke I. et al. BCR-ABL1-lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453(7191):110–4. DOI: 10.1038/nature06866. PMID: 18408710.Mullighan C.G., Miller C.B., Radtke I. et al. BCR-ABL1-lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453(7191):110–4. DOI: 10.1038/nature06866. PMID: 18408710.16. Olsson L., Castor A., Behrendtz M. et al. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia 2014;28(2):302–10. DOI: 10.1038/leu.2013.206. PMID: 23823658.Olsson L., Castor A., Behrendtz M. et al. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia 2014;28(2):302–10. DOI: 10.1038/leu.2013.206. PMID: 23823658.17. Boer J., van der Veer A., Rizopoulos D. et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2016;30(1):32–8. DOI: 10.1038/leu.2015.199. PMID: 26202931.Boer J., van der Veer A., Rizopoulos D. et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2016;30(1):32–8. DOI: 10.1038/leu.2015.199. PMID: 26202931.18. Kuiper R.P., Schoenmakers E.F., van Reijmersdal S.V. et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007;21(6):1258–66. DOI: 10.1038/sj.leu.2404691. PMID: 17443227.Kuiper R.P., Schoenmakers E.F., van Reijmersdal S.V. et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007;21(6):1258–66. DOI: 10.1038/sj.leu.2404691. PMID: 17443227.19. Mullighan C., Goorha S., Radtke I. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446(7137):758–64. DOI: 10.1038/nature05690. PMID: 17344859.Mullighan C., Goorha S., Radtke I. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446(7137):758–64. DOI: 10.1038/nature05690. PMID: 17344859.20. Martinelli G., Iacobucci I., Storlazzi C.T. et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease- free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009;27(31):5202–7. DOI: 10.1200/JCO.2008.21.6408. PMID: 19770381.Martinelli G., Iacobucci I., Storlazzi C.T. et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease- free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009;27(31):5202–7. DOI: 10.1200/JCO.2008.21.6408. PMID: 19770381.21. Nakayama H., Ishimaru F., Avitahl N. et al. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. Cancer Res 1999;59(16):3931–4. PMID: 10463586.Nakayama H., Ishimaru F., Avitahl N. et al. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. Cancer Res 1999;59(16):3931–4. PMID: 10463586.22. van der Veer A., Waanders E., Pieters R. et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013;122(15):2622–9. DOI: 10.1182/blood-2012-10-462358. PMID: 23974192.van der Veer A., Waanders E., Pieters R. et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013;122(15):2622–9. DOI: 10.1182/blood-2012-10-462358. PMID: 23974192.23. Buitenkamp T., Pieters R., Gallimore N. et al. Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012;26(10):2204–11. DOI: 10.1038/leu.2012.84. PMID: 22441210.Buitenkamp T., Pieters R., Gallimore N. et al. Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012;26(10):2204–11. DOI: 10.1038/leu.2012.84. PMID: 22441210.24. Dorge P., Meissner B., Zimmermann M. et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013;98(3):428–32. DOI: 10.3324/haematol.2011.056135. PMID: 22875627.Dorge P., Meissner B., Zimmermann M. et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013;98(3):428–32. DOI: 10.3324/haematol.2011.056135. PMID: 22875627.25. Jaeger R., Gisslinger H., Passamonti F. et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 2010;24(7):1290–8. DOI: 10.1038/leu.2010.99. PMID: 20508609.Jaeger R., Gisslinger H., Passamonti F. et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 2010;24(7):1290–8. DOI: 10.1038/leu.2010.99. PMID: 20508609.26. Chen I.M., Harvey R., Mullighan C. et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group Study. Blood 2012;119(15):3512–22. DOI: 10.1182/blood-2011-11-394221. PMID: 22368272.Chen I.M., Harvey R., Mullighan C. et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group Study. Blood 2012;119(15):3512–22. DOI: 10.1182/blood-2011-11-394221. PMID: 22368272.27. Palmi C., Valsecchi M.G., Longinotti G. et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica 2013;98(8):1226–31. DOI: 10.3324/haematol.2012.075432. PMID: 23585525.Palmi C., Valsecchi M.G., Longinotti G. et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica 2013;98(8):1226–31. DOI: 10.3324/haematol.2012.075432. PMID: 23585525.28. Öfverholm I., Tran A.N., Heyman M. et al. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. Leukemia 2013;27(9):1936–9. DOI: 10.1038/leu.2013.92. PMID: 23538749.Öfverholm I., Tran A.N., Heyman M. et al. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. Leukemia 2013;27(9):1936–9. DOI: 10.1038/leu.2013.92. PMID: 23538749.29. Bennett J., Catovsky D., Daniel M. et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33(4):451–8. PMID: 188440.Bennett J., Catovsky D., Daniel M. et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33(4):451–8. PMID: 188440.30. Bene M.C., Castoldi G., Knapp W. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9(10):1783–6. PMID: 7564526.Bene M.C., Castoldi G., Knapp W. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9(10):1783–6. PMID: 7564526.31. Béné M.C., Nebe T., Bettelheim P. et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European Leukemia Net Work Package 10. Leukemia 2011;25(4):567–74. DOI: 10.1038/leu.2010.312. PMID: 21252983.Béné M.C., Nebe T., Bettelheim P. et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European Leukemia Net Work Package 10. Leukemia 2011;25(4):567–74. DOI: 10.1038/leu.2010.312. PMID: 21252983.32. ISCN 2005: An International System for Human Cytogenetic Nomenclature (2005). Ed. by: L. Shaffer, N. Tommerup. Basel: Karger, 2005.ISCN 2005: An International System for Human Cytogenetic Nomenclature (2005). Ed. by: L. Shaffer, N. Tommerup. Basel: Karger, 2005.33. ISCN 2009: An International System for Human Cytogenetic Nomenclature(2009). Ed. by: L. Schaffer, M. Slovak, L. Campbell. Basel: Karger, 2009.ISCN 2009: An International System for Human Cytogenetic Nomenclature(2009). Ed. by: L. Schaffer, M. Slovak, L. Campbell. Basel: Karger, 2009.34. ISCN 2013: An International System for Human Cytogenetic Nomenclature(2013). Ed. by L. Schaffer, J. McGovan-Jordan, M. Schmid. Basel: Karger, 2013.ISCN 2013: An International System for Human Cytogenetic Nomenclature(2013). Ed. by L. Schaffer, J. McGovan-Jordan, M. Schmid. Basel: Karger, 2013.35. Цаур Г.А., Наседкина Т.В., Попов А.М. и др. Время достижения молекулярной ремиссии как фактор прогноза у детей первого года жизни c острым лимфобластным лейкозом. Онкогематология 2010;5(2):46–54. [Tsaur G.A., Nasedkina T.V., Popov A.M. et al. Prediction of outcome in infants acute lymphoblastic leukemia by time to achievement of molecular remission. Onkogematologiya = Oncohematology 2010;5(2):46–54. (In Russ.)].Цаур Г.А., Наседкина Т.В., Попов А.М. и др. Время достижения молекулярной ремиссии как фактор прогноза у детей первого года жизни c острым лимфобластным лейкозом. Онкогематология 2010;5(2):46–54. [Tsaur G.A., Nasedkina T.V., Popov A.M. et al. Prediction of outcome in infants acute lymphoblastic leukemia by time to achievement of molecular remission. Onkogematologiya = Oncohematology 2010;5(2):46–54. (In Russ.)].36. Цаур Г.А., Друй А.Е., Попов А.М. и др. Возможность использования микроструйных биочипов для оценки качества и количества РНК у пациентов с онкологическими и онкогематологическими заболеваниями. Вестник Уральской медицинской академической науки 2011;(4):107–11. [Tsaur G.A., Druy А.Е., Popov А.М. et al. Microfluidic biochips for RNA quantity and quality evaluation in patients with oncological disorders. Vestnik Ural’skoy meditsinskoy akademicheskoy nauki = Bulletin of the Ural Medical Academic Research 2011;(4):107–11. (In Russ.)].Цаур Г.А., Друй А.Е., Попов А.М. и др. Возможность использования микроструйных биочипов для оценки качества и количества РНК у пациентов с онкологическими и онкогематологическими заболеваниями. Вестник Уральской медицинской академической науки 2011;(4):107–11. [Tsaur G.A., Druy А.Е., Popov А.М. et al. Microfluidic biochips for RNA quantity and quality evaluation in patients with oncological disorders. Vestnik Ural’skoy meditsinskoy akademicheskoy nauki = Bulletin of the Ural Medical Academic Research 2011;(4):107–11. (In Russ.)].37. Литвинов Д.В., Карелин А.Ф., Романова К.И. и др. Лечение острого лимфобластного лейкоза у детей: современные возможности и нерешенные проблемы. Доктор.Ру 2015;(10):30–7. [Litvinov D.V., Karelin A.F., Romanova K.I. et al. Treatment of acute lymphoblastic leukemia in children: current possibilities and unsolved problems. Doctor.Ru 2015;(10): 30–7. (In Russ.)].Литвинов Д.В., Карелин А.Ф., Романова К.И. и др. Лечение острого лимфобластного лейкоза у детей: современные возможности и нерешенные проблемы. Доктор.Ру 2015;(10):30–7. [Litvinov D.V., Karelin A.F., Romanova K.I. et al. Treatment of acute lymphoblastic leukemia in children: current possibilities and unsolved problems. Doctor.Ru 2015;(10): 30–7. (In Russ.)].38. Smith M., Arthur D., Camitta B. et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14(1):18–24. DOI: 10.1200/jco.1996.14.1.18. PMID: 8558195.Smith M., Arthur D., Camitta B. et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14(1):18–24. DOI: 10.1200/jco.1996.14.1.18. PMID: 8558195.39. Moorman A.V., Ensor H.M., Richards S.M. et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010;11(5):429–38. DOI: 10.1016/S1470-2045(10)70066-8. PMID: 20409752.Moorman A.V., Ensor H.M., Richards S.M. et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010;11(5):429–38. DOI: 10.1016/S1470-2045(10)70066-8. PMID: 20409752.40. Цаур Г.А., Попов А.М., Фечина Л.Г., Румянцев С.А. Методические основы диагностики и мониторинга минимальной остаточной болезни при острых лейкозах у детей первого года жизни. Онкогематология 2016;11(1):62–74. [Tsaur G.A., Popov A.M., Fechina L.G., Rumyantsev S.A. Methodological aspects of diagnostics and minimal residual disease monitoring in infant acute leukemias. Onkogematologiya = Oncohematology 2016;11(1):62–74. (In Russ.)].Цаур Г.А., Попов А.М., Фечина Л.Г., Румянцев С.А. Методические основы диагностики и мониторинга минимальной остаточной болезни при острых лейкозах у детей первого года жизни. Онкогематология 2016;11(1):62–74. [Tsaur G.A., Popov A.M., Fechina L.G., Rumyantsev S.A. Methodological aspects of diagnostics and minimal residual disease monitoring in infant acute leukemias. Onkogematologiya = Oncohematology 2016;11(1):62–74. (In Russ.)].41. Попов А.М., Вержбицкая Т.Ю., Цаур Г.А. и др. Алгоритм применения проточной цитометрии для мониторинга минимальной остаточной болезни при CD10-негативном остром лимфобластном лейкозе из В-линейных предшественников. Вопросы диагностики в педиатрии 2012;(5):31–5. [Popov A.M., Verzhbitskaya T.Yu., Tsaur G.A. et al. Methodology of flow cytometry application for minimal residual disease monitoring in childhood CD10-negative B-cell precursor acute lymphoblastic leukemia. Voprosy diagnostiki v pediatrii = Diagnostics in Pediatrics 2012;(5):31–5. (In Russ.)].Попов А.М., Вержбицкая Т.Ю., Цаур Г.А. и др. Алгоритм применения проточной цитометрии для мониторинга минимальной остаточной болезни при CD10-негативном остром лимфобластном лейкозе из В-линейных предшественников. Вопросы диагностики в педиатрии 2012;(5):31–5. [Popov A.M., Verzhbitskaya T.Yu., Tsaur G.A. et al. Methodology of flow cytometry application for minimal residual disease monitoring in childhood CD10-negative B-cell precursor acute lymphoblastic leukemia. Voprosy diagnostiki v pediatrii = Diagnostics in Pediatrics 2012;(5):31–5. (In Russ.)].42. Попов А.М., Вержбицкая Т.Ю., Цаур Г.А. и др. Применение проточной цитометрии для определения минимальной остаточной болезни у детей с острым лимфобластным лейкозом, получающих терапию по протоколам со сниженной интенсивностью. Онкогематология 2015;10(4):44–55. [Popov А.M., Verzhbitskaya Т.Yu., Tsaur G.A. et al. Flow cytometric minimal residual disease monitoring in children with acute lymphoblastic leukemia treated by regimens with reduced intensity. Onkogematologiya = Oncohematology 2015;10(4):44–55.(In Russ.)].Попов А.М., Вержбицкая Т.Ю., Цаур Г.А. и др. Применение проточной цитометрии для определения минимальной остаточной болезни у детей с острым лимфобластным лейкозом, получающих терапию по протоколам со сниженной интенсивностью. Онкогематология 2015;10(4):44–55. [Popov А.M., Verzhbitskaya Т.Yu., Tsaur G.A. et al. Flow cytometric minimal residual disease monitoring in children with acute lymphoblastic leukemia treated by regimens with reduced intensity. Onkogematologiya = Oncohematology 2015;10(4):44–55.(In Russ.)].43. Schwab C., Jones L., Morrison H. et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010;49(12):1104–13. DOI: 10.1002/gcc.20818. PMID: 20815030.Schwab C., Jones L., Morrison H. et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010;49(12):1104–13. DOI: 10.1002/gcc.20818. PMID: 20815030.44. Yang Y., Hung C., Chen J. et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci 2011;102(10):1874–81. DOI: 10.1111/j.1349-7006.2011.02031.x. PMID: 21740479.Yang Y., Hung C., Chen J. et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci 2011;102(10):1874–81. DOI: 10.1111/j.1349-7006.2011.02031.x. PMID: 21740479.45. Olsson L., Ivanov Öfverholm I., Noren-Nystrom U. et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. Br J Haematol 2015;170(6):847–58. DOI: 10.1111/bjh.13514. PMID: 26018335.Olsson L., Ivanov Öfverholm I., Noren-Nystrom U. et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. Br J Haematol 2015;170(6):847–58. DOI: 10.1111/bjh.13514. PMID: 26018335.46. Volejnikova J., Mejstrikova E., Dörge P. et al. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia. Pediatr Blood Cancer 2013;60(3):420–7. DOI: 10.1002/pbc.24299. PMID: 22997141.Volejnikova J., Mejstrikova E., Dörge P. et al. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia. Pediatr Blood Cancer 2013;60(3):420–7. DOI: 10.1002/pbc.24299. PMID: 22997141.